RX Product News
Abilify
Marketed by:
Bristol-Myers Squibb Co(Princeton, NJ) and OtsukaPharmaceutical Co Ltd (Tokyo,Japan)
Indication:
May 8, 2008?The FDA approved updated labeling for Abilify (aripiprazole) as an adjunctive therapy to either lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in adults. Abilify has been approved as monotherapy for the treatment of manic and mixed episodes associated with bipolar I disorder with or without psychotic features in adults since September 2004. In addition to this new indication, the FDA approved a new recommended starting and target dose of 15 mg daily for Abilify monotherapy in the treatment of bipolar I disorder in adults.
Dosage Form:
Tablets: 2, 5, 10, 15, 20, and 30 mg; also available are Abilify Discmelt Orally Disintegrating Tablets: 10 and 15 mg; 1 mg/mL nonrefrigerated oral solution; singledose, ready-to-use solution for intramuscular injection, 7.5 mg/mL
For More Information:
Actonel
Marketed by:
Procter & Gamble Pharmaceuticals Inc (Cincinnati, OH) and sanofi-aventis US LLC (Bridgewater, NJ)
Indication:
April 24, 2008?The FDA approved a new once-a-month dose (150 mg) of Actonel (risedronatesodium) tablets for the treatment and prevention ofpostmenopausal osteoporosis. Actonel is a bisphosphonateapproved to reduce the risk of fractures inpostmenopausal women with osteoporosis. It also isindicated for treatment to increase bone mass in menwith osteoporosis, treatment and prevention of glucocorticoid-induced osteoporosis, and treatment ofPaget?s disease. With this approval, Actonel is the firstand only monthly option approved to protect womenfrom fracture at both the spine and sites beyond thespine.
Dosage Form:
Tablets: 5, 30, 35, 75, and 150 mg
For More Information:
Amitiza
Marketed by:
Sucampo PharmaceuticalsInc (Bethesda,MD) and TakedaPharmaceutical Co Ltd(Osaka, Japan) and its wholly owned subsidiary TakedaPharmaceuticals North America Inc (Deerfield, IL)
Indication:
April 29, 2008?Sucampo Pharmaceuticals Inc andTakeda Pharmaceutical Co Ltd and its wholly ownedsubsidiary, Takeda Pharmaceuticals North AmericaInc, announced that the FDA approved Sucampo?ssupplemental New Drug Application for Amitiza (lubiprostone)8-?g capsules twice daily to treat irritablebowel syndrome with constipation in women aged 18years or older. Amitiza, a chloride channel activator,received FDA approval in January 2006 and has beenavailable since April 2006 as a therapy for chronicidiopathic constipation in adults.
Dosage Form:
Gelatin capsules: 8 and 24 ?g
For More Information:
Ferralet 90
Marketed by:
Mission Pharmacal Co(San Antonio, TX)
Indication:
May 20, 2008?MissionPharmacal announced thelaunch of Ferralet 90, a newprescription oral iron supplementfor the treatment of irondeficiency anemia (IDA) that isresponsive to oral iron therapy.IDA is a depletion of storediron that prevents maturationof red blood cells. Ferralet 90contains 90 mg of carbonyliron as well as essential vitamins and minerals to helppatients replenish iron stores in a safe, effective, andtolerable manner. Iron deficiency is the most commonnutritional deficiency and the leading cause ofanemia in the United States.
Dosage Form:
One tablet daily or as directed by a physician (eachtablet contains 90 mg iron, 1 mg folic acid, 12 ?gvitamin B12, 120 mg vitamin C, and 50 mg docusatesodium)
For More Information:
Lacrisert
Marketed by:
Aton Pharma Inc(Lawrenceville, NJ)
Indication:
April 23, 2008?Aton Pharma Inc announced that it launched an expanded distribution program that incorporates sampling, reimbursement assistance, and patient education resources for the dry eye medication Lacrisert (hydroxypropyl cellulose ophthalmic insert). Lacrisert is a preservative-free, once-daily, sustained-release prescription insert that helps to retain moisture, stabilize the tear film, and lubricate the eye. Lacrisert has newly designed packaging, as well as a new national drug code. Lacrisert is administered into the inferior cul-de-sac of the eye beneath the base of the tarsus. It should not be placed in apposition to the cornea, nor beneath the eyelid at the level of the tarsal plate. Illustrated instructions are included in each package.
Dosage Form:
Ophthalmic insert: 5 mg supplied in packages of 60 sterile unit doses (each wrapped in an aluminum blister), 2 reusable applicators, and a plastic storage container to store the applicators after use
For More Information:
877-ATON-549 (877-286-6549)
Seroquel
Marketed by:
AstraZeneca(Wilmington, DE)
Indication:
May 14, 2008?AstraZeneca announced that the FDA approved Seroquel (quetiapine fumarate tablets) for the maintenance treatment of patients with bipolar I disorder, as adjunct therapy to lithium or divalproex. Seroquel is approved by the FDA for the treatment of schizophrenia, and it also is the only single agent approved by the FDA for the treatment of both depressive episodes in bipolar disorder and acute manic episodes associated with bipolar I disorder. Bipolar disorder currently affects approximately 8 million US adults and is considered one of the most severe forms of mental illness.
Dosage Form:
Tablets: 25, 50, 100, 200, 300, and 400 mg
For More Information:
Hot Rx
NovoSeven RT
Marketed by:
Novo Nordisk(Princeton, NJ)
Indication:
May 13, 2008?Novo Nordisk announced that the FDA approved NovoSeven RT (coagulation factor VIIa [recombinant] room temperature stable), the first room temperature?stable recombinant product available for the treatment of bleeding episodes in patients with hemophilia with inhibitors. NovoSeven RT is a new formulation of NovoSeven (coagulation factor VIIa [recombinant]) designed to provide patients with added flexibility when treating their condition. This new formulationdoes not need refrigeration and can be moved in and out of the refrigerator. In addition, NovoSeven RT has a higher concentration for lower infusion volumes and quick administration.
Dosage Form:
Lyophilized powder in single-use vials: 1, 2, or 5 mgrecombinant Factor VIIa
For More Information:
Vyvanse
Marketed by:
Shire plc(Philadelphia, PA)
Indication:
April 23, 2008?Shire plc announced that it received FDA approval for Vyvanse (lisdexamfetamine dimesylate), for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults. Vyvanse was originally approved in July 2007 for thetreatment of ADHD in children aged 6 to 12 years and is now the first and only once-daily prodrug stimulant approved to treat adults with ADHD. The recommended dosage for adults and pediatric patients aged 6 to 12 is 30 mg once daily in the morning; the maximum dose is 70 mg once daily in the morning. ADHD is one of the most common psychiatric disorders in children and adolescents and also affects an estimated 4.4% of US adults aged 18 to 44 based on results from the National Comorbidity Survey Replication.
Dosage Form:
Tablets: 20, 30 40, 50, 60, and 70 mg (dosage strengths of 20, 40, and 60 mg are expected to be available in pharmacies this summer)
For More Information:
